RxDoctor Payments DataLook up a doctor →

Shane Morgan, PA

Medical · Lincoln, RINPI 1437142213

Payments from drug & device makers

$24,182in general payments, 2019–2025

Across 1,279 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$5K
  • Johnson & Johnson$4K
  • LEO Pharma Inc.$2K
  • Sanofi$1K
  • Pfizer$1K
  • Incyte Corporation$1K
  • plus $9K from 28 others

What the payments were for

  • Food & beverage$23,33196%
  • Education$8514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,182 in reported general payments places this provider in the 95th percentile of 77 medical providers in Rhode Island.

See all medical providers in Rhode Island

Medicare billing

Part B allowed, 2024
$175,822
Medicare patients
677
Services billed
3,976

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SkyriziRisankizumab-Rzaa12$236,468
Humira(Cf) PenAdalimumab13$174,936
OtezlaApremilast22$99,702
Dupixent PenDupilumab16$82,957
RinvoqUpadacitinib13$80,964
Fluocinonide149$8,997
Clobetasol Propionate118$6,141
Ketoconazole337$6,133
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc160$4,508
Metronidazole67$3,819
Triamcinolone Acetonide298$3,709
Tacrolimus15$3,326
Clindamycin Phosphate69$2,984
Calcipotriene22$2,752
Desonide44$2,694

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi, Rinvoq$4,824$317,43225 claims
AmgenOtezla$845$99,70222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 77 medical providers in Rhode Island.

Other medical in Lincoln

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →